Development of vaccines against Zika virus

Poland, Gregory A.; Kennedy, Richard B.; Ovsyannikova, Inna G.; Palácios, Ricardo; Ho, Paulo Lee; Kalil, Jorge

doi:10.1016/s1473-3099(18)30063-x

Cited by 139 publications

(115 citation statements)

References 77 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Zika virus (ZIKV) probably emerged in the early 1900s and remained undetected for several years (1). This virus was first isolated in 1947 from a sentinel Rhesus monkey (Macaca mulatta) presenting febrile illness in Zika Forest, Uganda (2).…”

Section: Introductionmentioning

confidence: 99%

“…The first case of ZIKV in humans was reported in 1952 (3), and was historically regarded as a self-limiting disease. However, the scenario began to change in 2013, when a large outbreak in French Polynesia was associated with cases of Guillain-Barré syndrome (4) and during the outbreak in Brazil (2014)(2015), authorities reported an increased number of children born with microcephaly (1,5). Nowadays, infection by ZIKV is known to be associated with congenital neurological disorders (6).…”

Section: Introductionmentioning

confidence: 99%

“…Due to the devastating consequences of ZIKV infection, the WHO considers the development of preventive and therapeutic solutions a priority (9). Different vaccine models, including inactivated and attenuated models, have been tested in preclinical studies (1,11,12). Some of these models have shown success in mice, and some of them have advanced to the clinical stage (1,11,12).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus Infection

Vicente

Guedes-da-Silva

Dumard

et al. 2019

Preprint

View full text Add to dashboard Cite

Zika virus (ZIKV) emerged as an important infectious disease agent in Brazil in 2016. Infection usually leads to mild symptoms but severe congenital neurological disorders and Guillain-Barré syndrome have been reported following ZIKV exposure. The development of an effective vaccine against Zika virus is a public health priority, encouraging the preclinical and clinical studies of different vaccine strategies. Here, we describe the protective effect of an already licensed attenuated yellow fever vaccine (17DD) on type-I interferon receptor knockout mice (A129) and immunocompetent (BALB/c) mice infected with ZIKV. Yellow fever virus vaccination results in robust protection against ZIKV, with decreased mortality in the A129 mice, a reduction in the cerebral viral load in all mice, and weight loss prevention in the BALB/c mice. Despite the limitation of yellow fever (17DD) vaccine to elicit antibody production and neutralizing activity against ZIKV, we found that YF immunization prevented the development of neurological impairment induced by intracerebral virus inoculation in adult. Although we used two vaccine doses in our protocol, a single dose was protective, reducing the cerebral viral load. Different Zika virus vaccine models have been tested; however, our work shows that an efficient and certified vaccine, available for use for several decades, effectively protects mice against Zika virus infection. These findings open the possibility for using an available and inexpensive vaccine to a large-scale immunization in the event of a Zika virus outbreak.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus Infection

Vicente

Guedes-da-Silva

Dumard

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Given ZIKV pathogenesis and cell and tissue tropism, there is an urgent need to develop Zika vaccines that have the potential to protect the publicdespecially pregnant women and their fetusesdfrom ZIKV infection. 32…”

mentioning

confidence: 99%

Zika Vaccine Development: Current Status

Poland

Ovsyannikova

Kennedy

2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effectsdas well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.

show abstract

“…While ZIKV infection rates are certain to rise and fall cyclically, dependent at least in part on 440 weather patterns (particularly rainfall patterns and consequent mosquito density), it is expected 441 that the overall incidence of human infection will increase as more people are exposed to ZIKV of several putative vaccine candidates has also begun [43]. While these techniques probably 446 represent the best-case approach for dealing with ZIKV, the release of genetically modified 447 organisms is a topic that requires intense study and oversight by the FDA before it is approved.…”

mentioning

confidence: 99%

Monodelphis domesticaas a fetal intra-cerebral inoculation model for Zika virus pathogenesis

García

Terry

et al. 2019

Preprint

View full text Add to dashboard Cite

34Monodelphis domestica, also known as the laboratory opossum, is a marsupial native to South 35 America. At birth, these animals are developmentally equivalent to human embryos at 36 approximately 5 weeks of gestation which, when coupled with other characteristics including the 37 size of the animals, the development of a robust immune system during juvenile development, 38 and the relative ease of experimental manipulation, have made M. domestica a valuable model in 39 many areas of biomedical research. However, their suitability as models for infectious diseases, 40 especially diseases caused by viruses such as Zika virus (ZIKV), is currently unknown. Here, we 41 describe the replicative effects of ZIKV using a fetal intra-cerebral model of inoculation. Using 42 immunohistochemistry and in situ hybridization, we found that opossum embryos and fetuses are 43 susceptible to infection by ZIKV administered intra-cerebrally, that the infection persists long 44 term, and that the infection and viral replication consistently results in neural pathology and may 45 occasionally result in global growth restriction. These results demonstrate the utility of M. 46 domestica as a new animal model for investigating ZIKV infection in vivo. This new model will 47facilitate further inquiry into viral pathogenesis, particularly for those viruses that are 48 neurotropic, that may require a host with the ability to support sustained viral infection, and/or 49 that may require intra-cerebral inoculations of large numbers of embryos or fetuses. 50 AUTHOR SUMMARY 51Here we show that the laboratory opossum (Monodelphis domestica) is a valuable new model for 52 studying Zika virus pathogenesis. Newborns are at the developmental stage of 5-week human 53 embryos. Zika virus inoculated on a single occasion into the brains of pups at the human 54 developmental stages of 8-20 weeks post conception replicated in neuronal cells and persisted as 55 a chronic infection until the experimental endpoint at 74-days post infection. In addition, we 3 56 observed global growth restriction in one of 16 inoculated animals; global growth restriction has 57 been observed in humans and other animal models infected with Zika virus. The results illustrate 58 great potential for this new animal model for high throughput research on the neurological 59 effects of Zika virus infection of embryos and fetuses. 60 INTRODUCTION 61 Zika virus (ZIKV) is a small, enveloped positive-sense RNA virus from the family 62 Flaviviridae. Typically transmitted in a zoonotic cycle that alternates between a vertebrate host 63 and an invertebrate vector, ZIKV gained notoriety following the 2015 outbreak in Brazil, which 64 saw a dramatic increase in the number of neurological abnormalities in infants born to ZIKV-65 infected mothers [1]. Significant increases in Guillain-Barre syndrome and microcephaly during 66 this outbreak were also observed when compared to previous years [2], perhaps fulfilling the 67 theory posited by Hayes when he declared ZIKV to be neurovirulent [3...

show abstract

Development of vaccines against Zika virus

Cited by 139 publications

References 77 publications

Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus Infection

Yellow Fever Vaccine Protects Resistant and Susceptible Mice Against Zika Virus Infection

Zika Vaccine Development: Current Status

Monodelphis domesticaas a fetal intra-cerebral inoculation model for Zika virus pathogenesis

Contact Info

Product

Resources

About